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Background: Our purpose was to analyze and compare the use of direct health resources and costs generated in
the treatment of Dupuytren's contracture using two different techniques: subtotal fasciectomy and infiltration with
Collagenase Clostridium Histolyticum (CCH) in regular clinical practice at the Orthopedic and Traumatology Surgery
(OTS) Department at the Hospital de Denia (Spain).
Methods: Observational, retrospective study based on data from the computerized clinical histories of two groups
of patients- those treated surgically using a one or two digit subtotal fasciectomy technique (FSC) and those
treated with CCH infiltration, monitored in regular clinical practice from February, 2009 to May, 2012. Demographic
(age, sex), clinical (number of digits affected and which ones) and use of resources (hospitalizations, medical visits,
tests and drugs) data were collected. Resource use and associated costs, according to the hospital’s accounting
department, were compared based on the type of treatment from Spain’s National Health Service.
Results: 91 patients (48 (52.8%) in the FSC group) were identified. The average age and number of digits affected was
65.9 (9.2) years and 1.33 (0.48) digits affected in the FSC group, and 65.1 (9.7) years and 1.16 (0.4) digits in the CCH group.
Overall, the costs of treating Dupuytren's disease with subtotal FSC amount to €1,814 for major ambulatory surgery and
€1,961 with hospital stay including admission, surgical intervention (€904), examinations, dressings and physiotherapy.
As to collagenase infiltration, costs amount to €952 (including minor surgery admission, vial with product, office
examination and dressings). Finally, comparing total costs for treatments, a savings of €388 is estimated in favor of CCH
treatment in the best-case scenario (patient under MAS system with no need for physiotherapy) and €1,008 in the
worst-case scenario (patient admitted to hospital needing subsequent physiotherapy), implying a savings of 29% and
51%, respectively.
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Conclusions: This study demonstrates that treating patients with DC by injection with CCH at the OTS department of
the Hospital de Denia generates a total savings of 29% and 51% (€388 and €1008) compared with fasciectomy at the
time of treatment. Long term evolution of CCH treatment is uncertain and the recurrence rate unknown.
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Fibrosis in the superficial palmar aponeurosis, causing
the contracture of fingers in flexion, is known as
Dupuytren’s disease. Although its description is attributed
to Guillaume Dupuytren (1777–1835) after he published
the first edition of Leçons Orales in 1832 [1], it had
already been described by Astley Cooper [2]. Several fac-
tors are involved in its pathogenesis, among which are the
differentiation of fibroblasts into myofibroblasts, local
hyperemia, an increase of matrix protein synthesis (type
III collagen and fibronectin), and the final contraction of
these proteins, both at an intracellular and an extracellular
level, which is responsible for this disease [3].
With variable prevalence and incidence (3-6%), it is as-
sociated with Caucasian population groups from Northern
Europe [4,5]. There is no clear etiology of the pathology,
although some predisposing factors are known: genetic
factors, trauma, smoking, diabetes mellitus, aging, alcohol
consumption, several drugs (phenobarbital, protease in-
hibitors, isocyanide) and the presence of free radicals.
Once the disease is established, it demonstrates constant
progression, although this is variable over time. Factors for
early onset are family forms, young age at onset, concomi-
tant presence of Ledderhose disease or Dupuytren’s diath-
esis, and Knuckle pads [6].
Currently, treatment establishes surgical and non-
surgical approaches. Among the former, the treatment of
choice is fasciectomy, used in 80-90% of primary surgery
cases [4,5]. This is the most commonly used technique
in Spain [7], although there are other approaches in use,
including percutaneous cordectomy, Jacobsen-type flap
[8], dermofasciectomy or even amputation, as a last
option [6]. Non-surgical options [9] include needle
aponeurotomy or intralesional injection of various sub-
stances, such as corticosteroids, fibrinolysin, pepsin,
trypsin, hyaluronidase or thiomucase, all of which are
aimed at degrading collagen after infiltration of the cord
and show unsatisfactory clinical results.
Collagenase Clostridium Histolyticum (CCH) is an
exception to this last group, since it acts on the level of
degradation of types I and III collagen through two
different subtypes of enzymes belonging to the metal-
loprotease group [10]. It demonstrates favorable clinical
results following administration, with good or excellent
rates of improvement in 70-90% of cases [4,5,11]. Thesafety profile is extensive, since certain disorders in the
form of ecchymosis or even small skin openings at the
injection site in the soft tissues of the hand have fre-
quently been described. No cases of neurological or
vascular involvement have been observed, since the pre-
dominant collagen in these structures is type IV. Serious
complications, such as lysis of the tendon, have occa-
sionally been described [12]. Since its approval for mar-
keting in Europe in February 2011 [13], its use as an
alternative for Dupuytren’s contracture (DC) has demon-
strated the advantages of this non-invasive treatment
(rapid recovery, low rate of complications and minimal
skin alteration) and surgical treatments (eradication of
the disease and a lower rate of recurrence). Its use has
quickly spread throughout hand surgery units. The cre-
ation of infiltration and manipulation protocols in minor
surgery operating rooms is allowing CCH infiltration to
be gradually introduced as an alternative to fasciectomy,
thus allowing for the optimization of both clinical and
economic results for the center.
Objectives
To analyze and compare the use of direct healthcare re-
sources and the costs generated in the treatment of DC
using two different techniques: subtotal fasciectomy and
infiltration with Collagenase Clostridium Histolyticum
(Xiapex®) in regular clinical practice in the Orthopedic
and Traumatology Surgery (OTS) Department at the
Hospital de Denia (Spain).
Methods
Study design
This is an observational, retrospective study using data
from computerized clinical histories of two groups of pa-
tients followed-up in regular clinical practice starting at
the time of the official opening of the center in February,
2009 and continuing to May, 2012: A) patients surgically
treated using the subtotal fasciectomy technique on one
or two digits; B) patients subjected to Collagenase Clos-
tridium Histolyticum infiltration from the time of its
commercialization in Spain in September, 2011 at the
Orthopedic and Traumatology Surgery (OTS) Department
of the Hospital de Denia (Spain) to May, 2012. For the
inclusion of CCH patients in the surgery waiting list,
two assumptions were drawn in terms of registry and
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infiltration of soft joint tissue in the hand (coded in the
ICD-9 as 82.96 other injection of locally-acting
therapeutic substance into soft tissue of hand) with
subsequent manipulation (ICD-9 93.26 manual rupture
of joint adhesions) and a fasciectomy or fasciotomy
(both coded in the ICD-9 with codes 82.12 and 82.35
respectively). Enzymatic Aponeurotomy (EA) is the
name adopted for collagenase infiltration and the rup-
ture of the cord is being referred to as Enzymatic
Aponeurotomy Manipulation (EAM).
The authors declare that we have taken into account
the ethical responsibilities included in these standards
and that the procedures followed in the investigation are
in accordance with the ethical standards of the commit-
tee on human experimentation or animal responsible
(Ethics Committee of the research center) and in accor-
dance with the World Medical Association and the
Declaration of Helsinki.
Inclusion criteria
All the patients included in this study were adults, diag-
nosed with DC and treated by means of one of two tech-
niques: subtotal fasciectomy of one or two digits or
CCH infiltration. The hospital’s pharmacy committee ap-
proved a protocol for treatment using Xiapex® with a
maximum involvement of two digits per hand, usage
according to the drug's technical sheet, treatment in the
outpatient minor surgery unit and the construction of
EA and EAM indications for invoicing; accordingly, pa-
tients with more than two digits affected in a single
hand could not be treated with CCH and would be in-
cluded in the FSC group. These patients were excluded
from the study. Two patients had been previously
treated (but not included in the study) with the aim of
assessing the effectiveness of the July, 2011 treatment
under the specific requirements of compassionate treat-
ment before the official date of the drug's approval in
Spain. The results obtained encouraged us to design the
protocol and establish a generalized use for the drug. In
order to establish CCH as the treatment of choice for
DC in our center, we decided to compare our results
with those previously obtained with surgery. Written in-
formed consent was obtained from the patient for the
publication of this report and any accompanying images.
For the review, all patients diagnosed with DC were
selected by performing a computerized search of the
hospital’s database. In the group with fasciectomy, all pa-
tients operated on for one or more digits from February,
2009 to May, 2012 were included. Likewise, the CCH
group comprised patients treated from September, 2011
to May, 2012. Selection of treatment type was deter-
mined by the introduction of Xiapex® to the market-
place, the preferences and experiences of the surgeon,whether the surgeon had completed a training course
for CCH infiltrations, the number of digits affected, and
a clinical interview with the patient.
Study variables
Variables studied in both groups were age, sex, number
of digits affected and which ones, as well as degree of
contracture according to affectation as classified by the
British Society for Surgery of the Hand [14] (<30° light,
30-60° moderate and >60° severe) for the initial contrac-
ture and the results (0-5° excellent, 5-20° good and >20°
unsatisfactory) with a residual flexion of 0-5° being con-
sidered to be excellent, as specified by Gilpin [15], 0-20°
considered as good (the point used to define successful
treatment) and 20° as unsatisfactory. Tubiana´s classifica-
tion [16] of the patients is specified in Table 1. The
healthcare resources included were rehabilitation sessions
and OTS visits, as well as pre-operative preparation for
the group of patients who were surgically treated.
Costs
The approach selected was that of the National Health
Service of Spain. Therefore, only the direct costs of
healthcare were included, and indirect costs or expendi-
tures associated with medical leave due to DC treatment
were excluded. Table 2 shows all the different aspects of
the study and their economic determination. The deter-
mination of costs in the FSC group was obtained using
average surgical data measured by the center’s financial
department, updated in June, 2012 for both groups. The
valuation was conducted with respect to each of the pro-
cesses in consideration of potential billing, since ours is
a public hospital that is privately managed. Base parame-
ters for billing take into account the average duration of
surgical interventions, diagnosis according to the ICD-9
code and the basic costs applied to the use of the operat-
ing room with respect to an admission scheduled as
major ambulatory surgery (surgery without admission in
the major surgery operating room) or surgery with ad-
mission (surgery with an average stay of one night at the
center) and others factors. The second group (CCH
group) included the price of a CCH (Xiapex®) vial, as
well as all costs derived from its use in a protocoled
process of admission to the minor surgery unit (surgery
without admission in the mini-operating room with local
anesthesia). Both groups included pre- and post-
interventions, pre-operative visits when required, hos-
pital stays under the corresponding plans (surgery with
admission, major ambulatory surgery or minor surgery),
clinical and non-staff personnel involved in the process
and other associated costs (Table 3).
This cost was expressed in terms of average cost per
patient (€, June, 2012) for the main variables, in total,
for each study group, as well as a comparison
Table 1 Demographic and clinical variables according to
the type of treatment
Variable FSC (N = 48) CCH (N = 43)
Age (mean + SD) 65.9 (9.2) 65.1 (9.7)
Sex (male%) 83.3 88.4
Number of affected digits 64 50
Affected digits (average per patient) 1.33 (0.48) 1.16 (0.4)
Affectation 48 (100%) 43 (100%)
MCP 5 (10.4%) 7 (16.3%)
PIP 14 (29.2%) 12 (27.9%)
MCP + PIP 29 (60.4%) 24 (55.8%)
Contracture
MCP 34 (70,8%) 31 (72,1%)
20-30 6 (17.6%) 8 (25.8%)
30-60 13 (38.2%) 10 (41.9%)
>60 15 (44.1%) 13 (41.9%)
PIP 43 (89,6%) 36 (83,7%)
20-30 9 (20.9%) 6 (16.6%)
30-60 20 (46.5%) 16 (44.4%)
>60 14 (32.5%) 14 (38.8%)
Tubiana’s classification [16]
of treated radius
1 = 3 1 = 0
2 = 28 2 = 20
3 = 16 3 = 23
4 = 1 4 = 0
No statistically significant differences between groups (p > 0.05).




First OTS visit 56.03 56.03
Costs associated with surgery/treatment 748.51 904.05
2 Surgeons 229.34
1 Anesthetist 134.15
Non-staff personnel, field and circulating 180.62
Support personnel (assistants) 8.38
Specific surgical materials 327.47
Pharmacy 24,09
Mini-operating room (surgeon + nurse)* 22.21





Major ambulatory surgery (MAS) 121.32
Minor ambulatory surgery 77.28
Subsequent OTS visits
(average, mean cost)
1.23; 51.68 1.98; 83.20
Hospital care (average, mean cost) 0.74; 19.02 2.00; 51.42
Rehabilitation (frequency, number
of sessions, mean cost)
29%; 18.4; 473.83
OTS: Orthopedics and Traumatology Surgery, MAS: Major Ambulatory Surgery.
*Subjective cost of one working day of 6 hours for two consecutive days by
one surgeon, resulting in €16.21 per patient. The same scale is applied to a
single nurse present in the mini-operating room with a cost of €6.00 per
patient without any assistants.
Table 3 Costs of different items (euros) according to the
type of treatment
FSC Total FSC CCH Total CCH
Costs prior to surgery 181.07 56.03
Operating room costs 904.05 1085.12 748.51 804.54
Post-surgical costs (care + visits) 134.62 1219.74 70.70 875.24
MAS without RHB 121.32 1341.06
Admission without RHB 267.48 1487.22
RHB 473.83
MAS with RHB 1814.89
Admission with RHB 1961.05
Minor ambulatory surgery 77.28 952.52
FSC: Fasciectomy; CCH: Collagenase Clostridium Histolyticum; MAS: Major
Ambulatory Surgery; RHB: Rehabilitation. Minor ambulatory surgery requires
no admission and is performed in a mini-operating room.
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Data confidentiality
Prior to analysis, steps were taken to assure data confi-
dentiality. The study was classified by the Spanish Drug
and Health Products Agency (Agencia Española de
Medicamentos y Productos Sanitarios, Non-EPA) and
subsequently approved by the center’s Ethics Committee
for Clinical Research.
Results
A total of 91 DC patients were included, 48 (52.75%) in
the FSC group and 43 (47.25%) in the group treated
using CCH.
The group subject to subtotal fasciectomy surgery in-
cluded a total of 48 patients with a mean age of 65.9
(9.2) years (50–80 range) and a mean of 1.33 (0.48)
digits affected. The CCH group comprised 43 patients
aged 65.1 (9.7) years (48–87 range) and a mean of 1.16
(0.4) digits affected. There were no statistically signifi-
cant differences between the baseline characteristics of
the treatment groups.
All patients made a preliminary visit to the OTS de-
partment, where their conditions were assessed and abasic clinical history was created: clinical history and
data of interest were collected and patients were in-
formed of the procedure to be undertaken.
All patients treated with FSC were requested to
complete a pre-operative test (blood test with biochem-
istry, hemogram and coagulation, electrocardiogram,
and chest radiography if over the age of 60). Next, they
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evaluation. The CCH group had no pre-operative tests.
In the FSC group, a total of 48 patients were treated,
5 (10%) with isolated MCP involvement, 14 (29%) with
single alteration of the PIP and 29 (60%) with combined
affectation. Patients treated with CCH showed a single
involvement in the MCP in 7 (16%) cases and in the PIP
in 12 cases (28%). Combined cases added up to 24
(56%). Fingers affected were: 5th finger in 20 cases for
the FSC group and 25 for the CCH group, 4th finger in
21 and 17 respectively, 3rd finger in 4 and 1, and in the
FSC group, one 2nd finger and two 1st fingers were also
treated. A total of 29 infiltrations with collagenase were
performed at the MCP joint (14 in 5th finger, 14 in 4th
finger, and 1 in 3rd finger) and 14 at the PIP joint (11 in
the 5th finger and 3 in the 4th). Table 1 presents the data
corresponding to initial involvement.
In the FSC group, 39 (81.3%) of the patients were
treated under an outpatient hospitalization plan (major
ambulatory surgery) while 9 (18.7%) required hospital
admission for a day due to medical criteria (patients
with multiple pathologies, those who take oral anti-
coagulants and those with long-lasting brachial plexus
anesthesia or total anesthesia in surgeries performed in
the afternoon). In the CCH group, all patients were
treated under an outpatient plan (minor surgery).
In the FSC group, the operating room had two sur-
geons, one anesthetist, non-staff healthcare personnel
(field nurses and circulating nurses), support staff
(nurse’s aides), materials for both general surgical proce-
dures (gauzes, pads…) and those specific to that surgery
(hand surgery box), anesthesia and pharmacy-derived
costs. Operation room structural expenses, such as
power and water, were not included, since this room was
considered functional for this activity and for any other
for both groups. Taking this data into account, the costs
of the surgical intervention come to €904, with the ad-
mission plan (hospitalization or outpatient) to be added.
For the CCH infiltration, all patients went to the cen-
ter under an outpatient plan for minor surgery. In order
to optimize resources, patients were gathered into
groups (in three surgical sessions of 14, 16 and 13 sub-
jects; average of 14.3). Two consecutive days are re-
quired for this pharmacological treatment: the first for
the infiltration and the second for manipulation of the
cord. This allowed a record of the patient’s drugs to be
drawn up by the pharmacy department. Since the pro-
cedure was standardized, it allowed for simultaneous in-
voicing of the product, while maintaining the cold chain
supply from the pharmacy. For the patient, it also had
the advantage of his/her condition being monitored in
the non-admissions surgical unit (NASU) with the
assistance of non-staff members and nurses in case com-
plications should arise. Both the infiltrations and themanipulations took place in a mini-operating room in-
stead of at outpatient services. Expenses arising from the
CCH treatment stemmed from the cost of the vial of
product, non-staff personnel (only a trauma doctor and a
nurse were present, with no anesthetist or other support
staff needed) and materials for dressings and injection.
After the surgery, patients were examined and their
wounds dressed in the hospital consultation office. The
date for the first follow-up visit for patients in the FSC
group was 4–5 days after the intervention, coinciding
with the first day of visits by the authors for the assess-
ment of the surgical wounds. In the CCH group with
skin opening, phlyctena with hemorrhagic content or
any type of complication, the first visit took place after
those same 4–5 days. If there were no problems, patients
were asked to return after 1, 3 and 6 months in order to
assess the functional results of the treatment. The aver-
age number of medical examinations was 2 and the
number of hospital dressings was also 2 in the FSC
group. A total of 14 patients required visits to the re-
habilitation department, with an average of 18.43 physio-
therapy sessions (range 10–45) involving an average cost
of €473.
In the CCH group, the evolution of the CORD I and
CORD II [15,17] study protocols were followed, with
subsequent control visits at 3, 6, and 12 months (mean
of 1.23 visits). The infiltration of a different digit or hand
was considered a new starting point, rather than a sub-
sequent visit. When the study was performed, only the
check-ups for months 3 and 6 had been completed for
certain patients. The rate of hospital care in terms of
skin openings or any other complication was 0.74.
The average correction of the contracture with CCH
infiltration at the MCP joint in an isolated manner was
88% of the initial contracture with an average correction
of 42°. 4 cases showed an excellent result (0-5° contrac-
ture), 2 a good result (5-20°) and 1 unsatisfactory.
Regarding PIP, the average correction was 32° (52%) with
4 cases considered to have an excellent result, 1 good
and 7 unsatisfactory. In those patients in which infiltra-
tion was performed at the MCP or PIP with involvement
of another joint in the same digit (infiltration was made
in the most affected), the average correction was
40° (87%) in the MCP joint (17 excellent results, 5 good
and 2 unsatisfactory) and 29° (67%) for the PIP (9 excel-
lent, 8 good and 7 unsatisfactory results). Table 4 shows
comparative data of the results among groups.
The CCH group had a greater complication rate (2%)
due to a patient with intense hyperesthesia in the punc-
ture site. This was intense and continuous and did not
ease with any medical or physiotherapeutic treatment
type, and a dermofasciectomy was performed, which
cured the condition [15]. A total of 3 early recurrences
(7%) were observed and could be due to defects in the
Table 4 Results of the treatment in both groups
CCH FSC
Total Def Ext med N° patients Mean (%) Range Average correction° Range Def ext med N° patients Mean (%)
MCF 12 31 77 0-100 36 0-94 10 34 91,4
0-5 2,3 21 99 43 4,1 19 97,4
5-20 12 6 77 44 7 11 92,3
>20 57 4 25 19 26 4 85,6
IFP 21 31 57 0-100 27 0-80 17 43 64,4
0-5 1,3 9 98 41 4,6 17 93,1
5-20 13 10 63 30 14 19 70,1
>20 49 12 26 16 30 7 48,7
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the first batch of infiltrations, and their results, although
unsatisfactory, were included in the result statistics. In
one case, the presence of air in the barrel of the syringe
caused the administration of a lower medication dose to
the patient, which was probably the cause of treatment
failure. The other two cases were unsatisfactory infiltra-
tions at the ulnar flanges of the 5th finger. In both cases,
surgery was performed by means of subtotal fasciec-
tomy; in one case the patient did not accept further
treatment. All problems with CCH were detected at the
time of the first follow-up visit one month after inter-
vention, and reoccurrences saw the patients’ conditions
brought back to the same degree as before the infiltra-
tion. Thus, we conclude that it was a probably technical
problem which affected only the first cases treated. In
the FSC group, greater complications were found in
9 (20%) patients: 1 digital nerve lesion, 3 cases of infec-
tion, 2 cases of stiffness solved with intensive physiother-
apy, 2 cases of CRPS (complex regional pain syndrome)
and 1 amputation.
Finally, comparing the full costs of both treatments, a
total savings of €388 is estimated in favor of CCH treat-
ment in the best case scenario for FSC (patient under
MAS plan with no need for physiotherapy) and €1,008
in the worst case scenario for FSC (patient admitted to
hospital needing subsequent physiotherapy), thus signi-
fying a total savings of 29% and 51.5%, respectively
(Figure 1).
Discussion
There are no current studies assessing the costs associ-
ated with DC treatment in Spain that include CCH
treatment. This is the first study comparing the use of
resources and expenses related to surgical treatment
with fasciectomy versus CCH infiltration under condi-
tions of regular clinical practice. De Salas-Cansado [18]
compared fasciectomy procedures at three primary hos-
pitals in Spain. The average total cost per treatment was
€2,250. Costs varied according to hospital and admission
plan, but were quite similar to our conclusions: patientsadmitted had a cost of €2,467 compared to €1,961 in our
study, and ambulatory patients had a cost of €1,703
compared to €1,815 in our study. The difference lay pri-
marily in the cost of the hospital stay, since costs derived
exclusively from the surgery itself were also quite similar
(€1,074 compared to €904, respectively). An increase in
the number of ambulatory patients, especially in the
mild stages of DC and those with few co-morbidities, is
proposed in this article. In our case, the use of local
anesthesia and the presence of a recovery room adjacent
to the mini-operating room where CCH treatments took
place allowed us to include all patients in the minor sur-
gery plan, as we were able to maintain adequate moni-
toring of patients after infiltration and manipulation,
thus minimizing costs and resources.
Chen [19] established a cost-utility analysis comparing
several techniques based on quality-adjusted life years
(QALY) by creating several possible situations. The
study concluded that CCH is a cost-effective treatment
with a treatment cost of less than $945 (€730) (in Spain,
the current price of Xiapex© is €725 per vial) with asso-
ciated costs of $122 (€94.20) for the injection, and a
resulting total of €824, which is quite similar to our esti-
mate for the treatments in which only one injection is
required and the cost of subsequent examinations are
not included (we did include these). Therefore, our re-
sults are more economical.
The most extensive population study may be that
presented by Gerber [20], which included more than
60,000 NHS cases. This study did not consider the use
of CCH. Among the registered treatment options,
fasciectomy was used in 91% of cases for the treatment
of DC. The average established costs were £2,885
(€3,579) for ambulatory patients and £3,534 (€4,384) for
admitted patients. There was also a difference with the
price of digital palmar fasciectomy, which was more ex-
pensive. Although estimated costs varied according to
the hospital and the condition of the patient, they are
significantly higher than those represented in our geo-
graphical area. In France [11], the cost of fasciectomy
has been established only for admitted patients over the
Figure 1 Cumulative costs of different items according to the type of treatment and admission.
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ences in costs between public and private sectors, and
changes in costs since the article’s date of publication
(2005) nullify the validity of these findings with respect
to the parameters we are now studying. In addition, this
author overestimated costs, since ambulatory patients
were not considered. The price of percutaneous fasciec-
tomy was unusual, since it was priced at €37 for one
hand and €65 for two hands.
Even though needle fasciectomy is by far the cheapest
treatment, recurrence rates, varying after 5 years from
50-85% [21,22], make this treatment type unacceptable,
since education and physiotherapy costs (frequently not
offset due to the quick recurrence of the disease) have to
be added to the advantages of a minimally aggressive
procedure. In one analysis, Chen [19] conducted an add-
itional review of the recurrence rate according to the
technique used for the treatment of DC and concluded
that needle fasciotomy had a recurrence rate of 60%,
fasciectomies 30% and CCH infiltration only 15% for a
complete treatment of 3 injections. A review of the lit-
erature provides recurrence rates between 15 and 46%
for surgery, 0 to 75% for CCH, 12 to 65% for needle
fasciotomy, 12% for dermofasciectomy, and 23% for skel-
etal traction, with great variability regarding the time of
evolution and no consensus as to the definition of recur-
rence [6,14,15,21-27].
For our regional healthcare system, the government
for the region of Valencia for the 2012 [28] fiscal year
established prices for hospital processes according to
DRG (diagnosis-related groups). These were used for
correlating different types of patients treated in a
hospital with the costs incurred for their care. There was
no specific DRG for DC, although it was normally in-
cluded in DRG228 (major thumb or joint procedures or
other hand or wrist procedures) or DRG229 (hand or
wrist procedures, except major joint procedures). The
amounts allocated for both codes were €3,501.59 and€2,799.03, respectively. These were much higher than
our findings and about 290-360% more expensive than
infiltration with CCH at our center. Currently, Enzym-
atic Aponeurotomy is not included in the treatment with
CCH, nor is CCH infiltration specified, although in the
rehabilitation section, a cost of €677.96 is established for
infiltration with botulinum toxin (PR1201), which would
be the most approximate option. The price of the vial to
be infiltrated and the subsequent manipulation, as con-
comitant therapy, should be added on.
For the treatment of DC, the use of CCH in surgery
units without admission allows for a combination of treat-
ment efficacy with minimal aggression and hospitalization.
Results are good with AVS after infiltration at a one
month clinical revision, as is patient satisfaction. In
addition, CCH optimizes healthcare resources, at the
present time a scarce commodity. Our study presents the
costs in a detailed and exhaustive manner for both alterna-
tives assessed, since aside from hospital expenses, it also
includes all costs for follow-up visits and post-operative
rehabilitation. However, several limitations must be noted.
The first limitation is related to the progress of treatment
with CCH, because even though 8-year progress studies
[24] are available, the number of cases involved does not
allow us to draw conclusions regarding the long-term pro-
gress of these patients after fasciectomy. Rates of early re-
currence and other types of disorders (such as skin
retractions) should also be assessed. These might show
unsatisfactory results over the short term. Another limita-
tion is related to costs, because the inflation rate in Spain
has been 2.76% from June, 2012 to the present time, so
that all costs of the process have increased to this extent.
The inflation rate in the rest of the Euro area has been
only 2.29% for the same period and this will affect values
when comparing our data with those of other countries.
The price per dose of Xiapex® has not changed.
With respect to our economic assessment, it is esti-
mated per process, that is, per infiltration. Therefore, in
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or three infiltrations, the price is doubled and tripled, re-
spectively, since this scenario is not considered a recur-
rence. Likewise, patients with two or even three digits
affected that are resolved using a single infiltration should
be considered differently, because the final cost of the
treatment is then reduced when compared to one hand,
since treatment with CCH is initially conceived to be used
in only one joint per treatment. The results in our study
indicate a rate of those affected of 1.16 for the CCH and
1.33 with surgery (p > 0.05). That entails a reduction, in
many cases, of 2 or even 3 digits with a single Xiapex© in-
filtration, especially in cords at the metacarpophalangeal
(MCP) joint that are of natatory or Y types.
The results obtained with CCH are clinically similar to
those of the FSC group. Fewer major complications have
been observed in the CCH group at midterm, and infil-
tration with collagenase in one finger, on many occa-
sions, treats two joints. The explanation for not meeting
the criteria in the technical sheet with 3 vials is two-fold
in our environment. First of all, it is related to patients;
the infiltration is frequently painful and performed with
no anesthesia. When patients experience a significant
improvement of the contracture, sufficient for perfor-
ming both work and daily activities, they sometimes
reject further treatment, and do not obtain the good or
excellent correction that might have been achieved. This
is the case with those patients suffering severe MCP and
PIP involvement, in which MCP is completely corrected
and 30° remain, for example, of PIP flexion. The second
reason is related to infrastructure; it is very difficult to
schedule and carry out a second infiltration just one
month after the first one for those patients who did not
achieve a satisfactory outcome, and practically impos-
sible to schedule a third one.
Our results with the use of CCH are similar to those
of Hurst [17]. Clinical improvement in the second end
point is somewhat lower in our results (74% in our study
as opposed to 84.7% in the Hurst study). On the other
hand, ROM improvement is similar (an average of 36° in
our study compared to 41° in the Hurst study for the
MCP and an average of 27° versus 29° respectively in the
PIP joint). The minor correction of 5 degrees for both
the MCF and the IFP is lower in our study, which may
be due to several factors: the use of only one infiltration,
the initial learning curve, or the presence of very marked
contractures.
Regarding the recurrence rate, it is too soon to deter-
mine the problems that may appear in the long term for
those patients treated in the CCH group. The average
follow up time in the study does not allow us to make
valid predictions as to the recurrence rate for these pa-
tients, although the results seem promising. Study data
are upfront costs in CD. Long term evolution of CCHtreatment is uncertain and the recurrence rate unknown,
although the systematic review conducted by Chen [29]
seems to indicate that the use of CCH has a lower rate
of recurrence than does FSC. At the present time, we
consider CCH as a definitive treatment or as a treatment
that may reduce the number of patients needing surgery
over time [30], especially for those with lower degrees of
contracture and isolated involvement of the MCP joint.
Conclusions
In the short term, treatment with CCH infiltration re-
flects a 29 to 51.5% decrease in healthcare costs (€388 -
€1,008) and in use of resources in comparison with the
treatment of choice for DC: fasciectomy. Assigning the
codes Enzymatic Aponeurotomy (EA) and Enzymatic
Aponeurotomy Manipulation (EAM) to the process al-
lows for registering and monitoring both processes and
patients for adequate treatment and future procedures.
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